These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25080553)

  • 21. Post-licensure experience with rotavirus vaccination in Latin America and the Caribbean: a systematic review and meta-analysis.
    Chavers T; De Oliveira LH; Parashar UD; Tate JE
    Expert Rev Vaccines; 2018 Nov; 17(11):1037-1051. PubMed ID: 30365904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial.
    Armah GE; Sow SO; Breiman RF; Dallas MJ; Tapia MD; Feikin DR; Binka FN; Steele AD; Laserson KF; Ansah NA; Levine MM; Lewis K; Coia ML; Attah-Poku M; Ojwando J; Rivers SB; Victor JC; Nyambane G; Hodgson A; Schödel F; Ciarlet M; Neuzil KM
    Lancet; 2010 Aug; 376(9741):606-14. PubMed ID: 20692030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants.
    Laserson KF; Nyakundi D; Feikin DR; Nyambane G; Cook E; Oyieko J; Ojwando J; Rivers SB; Ciarlet M; Neuzil KM; Breiman RF
    Vaccine; 2012 Apr; 30 Suppl 1():A61-70. PubMed ID: 22520138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of human rotavirus vaccine on severe diarrhea in African infants.
    Madhi SA; Cunliffe NA; Steele D; Witte D; Kirsten M; Louw C; Ngwira B; Victor JC; Gillard PH; Cheuvart BB; Han HH; Neuzil KM
    N Engl J Med; 2010 Jan; 362(4):289-98. PubMed ID: 20107214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule.
    Buttery JP; Lambert SB; Grimwood K; Nissen MD; Field EJ; Macartney KK; Akikusa JD; Kelly JJ; Kirkwood CD
    Pediatr Infect Dis J; 2011 Jan; 30(1 Suppl):S25-9. PubMed ID: 21183837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of routine rotavirus vaccination on all-cause and rotavirus hospitalizations during the first four years following vaccine introduction in Rwanda.
    Sibomana H; Rugambwa C; Mwenda JM; Sayinzoga F; Iraguha G; Uwimana J; Parashar UD; Tate JE
    Vaccine; 2018 Nov; 36(47):7135-7141. PubMed ID: 29754701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Rotavirus Vaccines on Gastroenteritis Hospitalizations in Western Australia: A Time-series Analysis.
    Fathima P; Jones MA; Moore HC; Blyth CC; Gibbs RA; Snelling TL
    J Epidemiol; 2021 Aug; 31(8):480-486. PubMed ID: 32801278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct, indirect, total, and overall effectiveness of the rotavirus vaccines for the prevention of gastroenteritis hospitalizations in privately insured US children, 2007-2010.
    Panozzo CA; Becker-Dreps S; Pate V; Weber DJ; Jonsson Funk M; Stürmer T; Brookhart MA
    Am J Epidemiol; 2014 Apr; 179(7):895-909. PubMed ID: 24578359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of monovalent rotavirus vaccine in a high-income, predominant-use setting.
    Doll MK; Buckeridge DL; Morrison KT; Gagneur A; Tapiero B; Charest H; Quach C
    Vaccine; 2015 Dec; 33(51):7307-7314. PubMed ID: 26546262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pentavalent rotavirus vaccine (RotaTeq): a review of its use in the prevention of rotavirus gastroenteritis in Europe.
    Plosker GL
    Drugs; 2010 Jun; 70(9):1165-88. PubMed ID: 20518582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics of an ideal rotavirus vaccine.
    Reisinger KS; Block SL
    Clin Pediatr (Phila); 2008 Jul; 47(6):555-63. PubMed ID: 18467670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction of hospitalizations with diarrhea among children aged 0-5 years in Nouakchott, Mauritania, following the introduction of rotavirus vaccine.
    Ahmed MC; Heukelbach J; Weddih A; Filali-Maltouf A; Sidatt M; Makhalla K; Dahdi S; Cheikh Ahmed AC; El-Mami MV; Tate JE; Parashar UD; Benhafid M
    Vaccine; 2019 Mar; 37(11):1407-1411. PubMed ID: 30765173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of a monovalent rotavirus vaccine in infants in Malawi after programmatic roll-out: an observational and case-control study.
    Bar-Zeev N; Kapanda L; Tate JE; Jere KC; Iturriza-Gomara M; Nakagomi O; Mwansambo C; Costello A; Parashar UD; Heyderman RS; French N; Cunliffe NA;
    Lancet Infect Dis; 2015 Apr; 15(4):422-8. PubMed ID: 25638521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled Phase I studies.
    Li RC; Li YP; Mo ZJ; Luo D; Huang T; Kong JL; Wang LH; Song NS; Liu A; Zhang H; Liao X; Karkada N; Han HH
    Hum Vaccin Immunother; 2013 Aug; 9(8):1638-42. PubMed ID: 23807360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rotavirus Vaccine Safety and Effectiveness in Infants With High-Risk Medical Conditions.
    van Dongen JAP; Rouers EDM; Schuurman R; Band C; Watkins SM; van Houten MA; Bont LJ; Norbruis OF; Hemels MAC; van Well GTJ; Vlieger AM; van der Sluijs J; Stas HG; Tramper-Stranders G; Kleinlugtenbeld EA; van Kempen AAMW; Wessels M; van Rossem MC; Dassel CACM; Pajkrt D; Bonten MJM; Bruijning-Verhagen PCJ
    Pediatrics; 2021 Dec; 148(6):. PubMed ID: 34814164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential impact of accelerating the primary dose of rotavirus vaccine in infants.
    Halvorson EE; Peters TR; Snively BM; Poehling KA
    Vaccine; 2012 Apr; 30(17):2738-41. PubMed ID: 22374373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-World Effectiveness of Pentavalent Rotavirus Vaccine Among Bedouin and Jewish Children in Southern Israel.
    Leshem E; Givon-Lavi N; Tate JE; Greenberg D; Parashar UD; Dagan R
    Clin Infect Dis; 2016 May; 62 Suppl 2():S155-60. PubMed ID: 27059350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accounting for indirect protection in the benefit-risk ratio estimation of rotavirus vaccination in children under the age of 5 years, France, 2018.
    Escolano S; Mueller JE; Tubert-Bitter P
    Euro Surveill; 2020 Aug; 25(33):. PubMed ID: 32820718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen).
    Dennehy PH; Vesikari T; Matson DO; Itzler RF; Dallas MJ; Goveia MG; DiNubile MJ; Heaton PM; Ciarlet M
    Hum Vaccin; 2011 May; 7(5):563-8. PubMed ID: 21441783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spotlight on pentavalent rotavirus vaccine (RotaTeq) in the prevention of rotavirus gastroenteritis in Europe.
    Plosker GL
    BioDrugs; 2010 Dec; 24(6):411-4. PubMed ID: 21043548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.